Document Detail

Drug interactions with irbesartan.
MedLine Citation:
PMID:  11523726     Owner:  NLM     Status:  MEDLINE    
Irbesartan is an angiotensin II receptor antagonist indicated for the treatment of patients with hypertension. Although irbesartan does not require biotransformation for its pharmacological activity, it does undergo metabolism via the cytochrome P450 (CYP) 2C9 isoenzyme and negligible metabolism by the CYP3A4 isoenzyme. The long term treatment of patients with hypertension is generally required for effective management of the disease, and the use of concurrent medications is usually inevitable. This paper reviews the drug and food interaction trials involving irbesartan that have been conducted to date. Based on the available literature, no significant interactions have been identified between irbesartan and hydrochlorothiazide, nifedipine, simvastatin, tolbutamide, warfarin, magnesium and aluminum hydroxides, digoxin or food. Fluconazole did increase the steady-state peak plasma concentration (by 19%) and area under the concentration-time curve (by 63%) of irbesartan, but these increases are not likely to be clinically significant. In summary, irbesartan has demonstrated minimal potential for drug or food interactions in trials conducted to date.
M R Marino; N N Vachharajani
Related Documents :
8861776 - Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance.
19442216 - Binding of cyp2c9 with diverse drugs and its implications for metabolic mechanism.
411946 - Lead intoxication among demolition workers: the effect of lead on the hepatic cytochrom...
20118446 - The pharmacokinetics of paliperidone versus risperidone.
15626586 - Multiple p450 substrates in a single run: rapid and comprehensive in vitro interaction ...
17673246 - Timolol transport from microemulsions trapped in hema gels.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Clinical pharmacokinetics     Volume:  40     ISSN:  0312-5963     ISO Abbreviation:  Clin Pharmacokinet     Publication Date:  2001  
Date Detail:
Created Date:  2001-08-28     Completed Date:  2002-01-10     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7606849     Medline TA:  Clin Pharmacokinet     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  605-14     Citation Subset:  IM    
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 18543, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / metabolism,  pharmacokinetics,  therapeutic use*
Area Under Curve
Biphenyl Compounds / metabolism,  pharmacokinetics,  therapeutic use*
Drug Interactions*
Hypertension / drug therapy*
Intestinal Absorption
Randomized Controlled Trials as Topic
Tetrazoles / metabolism,  pharmacokinetics,  therapeutic use*
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Tetrazoles; 138402-11-6/irbesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pharmacogenetics of warfarin elimination and its clinical implications.
Next Document:  Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in ...